Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Interleukin 4 modulates microglia homeostasis and attenuates the early slowly progressive phase of amyotrophic lateral sclerosis.

Cell death & disease·2018
Same author

Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks.

Neurology·2018
Same author

Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks.

Neurology·2018
Same author

Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing-remitting multiple sclerosis: the CLARITY Extension study.

Therapeutic advances in neurological disorders·2018
Same author

Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study.

Multiple sclerosis (Houndmills, Basingstoke, England)·2018
Same author

ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2018

Related Experiment Video

Updated: May 7, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Disease-modifying treatments for progressive multiple sclerosis.

Giancarlo Comi1

  • 1Department of Neurology, Università Vita-Salute San Raffaele, Italy.

Multiple Sclerosis (Houndmills, Basingstoke, England)
|September 25, 2013
PubMed
Summary
This summary is machine-generated.

Treatments for relapsing-remitting multiple sclerosis (RRMS) show promise, but progressive forms like primary progressive multiple sclerosis (PPMS) remain challenging. New research explores immune and neuroprotective strategies for all multiple sclerosis (MS) types.

Keywords:
Multiple sclerosisdisease-modifying therapiesprogressive multiple sclerosis

More Related Videos

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis
08:11

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Published on: November 14, 2016

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

Related Experiment Videos

Last Updated: May 7, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis
08:11

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Published on: November 14, 2016

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

Area of Science:

  • Neuroimmunology
  • Neurodegenerative Diseases
  • Clinical Trials

Background:

  • Significant advancements in treating relapsing-remitting multiple sclerosis (RRMS) over two decades, primarily through immunomodulatory drugs.
  • Limited success of immune-targeting therapies in primary progressive multiple sclerosis (PPMS) and secondary progressive multiple sclerosis (SPMS) clinical trials.
  • Emerging understanding of the complex interplay between inflammation and neurodegeneration in multiple sclerosis (MS) progression.

Purpose of the Study:

  • To provide an updated review of clinical trials for progressive multiple sclerosis (MS).
  • To analyze the rationale and outcomes of therapies targeting immune dysfunction and neuroprotection in PPMS and SPMS.
  • To discuss future research directions based on current findings and evolving scientific concepts.

Main Methods:

  • Systematic review of published clinical trials in primary and secondary progressive multiple sclerosis.
  • Analysis of studies employing immune-targeting agents.
  • Evaluation of studies investigating neuroprotective strategies.

Main Results:

  • Immune-targeting drugs effective in RRMS have largely failed in PPMS and shown limited efficacy in SPMS.
  • The discrepancy in treatment outcomes highlights differing pathological mechanisms in MS subtypes.
  • Neuroprotection strategies are being explored as a potential avenue for progressive MS.

Conclusions:

  • Current immunotherapies are insufficient for halting progression in PPMS and SPMS.
  • A deeper understanding of neuroinflammation and neurodegeneration is crucial for developing effective progressive MS treatments.
  • Future research should integrate insights from RRMS, progressive MS trials, and basic science to develop novel therapeutic approaches.